Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction

New Zealand Medical Journal

Volumn 130, Issue 1452, 2017, Pages 9-16

  Oliphant, Jeannie ^a   Stewart, Joanna ^b   Saxton, Peter ^b   Lo, Min ^c   Perkins, Nicky ^a   Ward, Daniel ^d  

^a GREEN LANE HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Auckland Sexual Health Service   (New Zealand)

^d Taunton and Somerset Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; ETHNIC GROUP; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGRAM EFFICACY; RETROSPECTIVE STUDY; RISK FACTOR; VACCINATION; CAUCASIAN; CONDYLOMATA ACUMINATA; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PAPILLOMAVIRUS INFECTIONS; POPULATION GROWTH; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

CONDYLOMATA ACUMINATA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MALE; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PAPILLOMAVIRUS INFECTIONS; POPULATION GROWTH; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 85016165504     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6,11,16 and 18) vaccine. J Infect Dis. 2009; 199:805–14.
2. Brotherton JML. Human papillomavirus vaccination: where are we now? Journal of Paediatrics and child health. 2014; 50:959–65.
3. Hammad A, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346:2032.
4. th May 2016.
5. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. NZMJ. 2011; 124:51–8.
6. Wilson N, Morgan J, Baker MG. Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand. Sex Transm Infect 2014; 90:103.
7. Clark TC, Fleming T, Bullen P, et al. (2013). Youth’12 Overview: The health and wellbeing of New Zealand secondary school students in 2012. Auckland, New Zealand: The University of Auckland.
8. Blakely T, Kvizhinadze G, Karvonen T, et al. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine 2014; 32:2645–56.
9. Blakely T, Shaw C, Atkinson J, et al. Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981–1986 to 2001–2004. Cancer Causes Control 2011; 22:130718.
10. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systemic review and meta-analysis. Lancet Infect Dis 2015; 15:565–80.
11. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of Ten Years of Real-World Experience. Clin Infect Dis. 2016 May 26: Online First.
12. Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus infection. Sexual Health. 2010; 7:244–52.